- DIAN-TU Study: GHR is one of the funders of the Washington University study to quickly evaluate potential prevention treatments among people most likely to develop the disease. Trial participant Daisy Duarte was recently profiled in People Magazine. This article, along with Oscar attention for “Still Alice”—a film about a woman with early-onset Alzheimer’s—is helping to bring prevention research into the public spotlight.
- Anti-Amyloid Treatment in Asymptomatic Alzheimer's Study (A4): GHR is also contributing to the A4 Harvard study that is designed to identify and treat patients in the earliest stages of Alzheimer's, before memory loss begins. Recently, A4 researchers conducted the first scans in a clinical trial for the presence of the protein tau, which forms toxic tangles of nerve fibers associated with Alzheimer's. The addition of tau imaging into this trial was directly funded by GHR and is our primary contribution to the study. The breakthrough scans will enable researchers to see the effects of an experimental drug on both amyloid plaques and tau tangles for the first time, potentially leading to more effective prevention and treatments.
Recent headlines document important milestones in the fight against Alzheimer's. GHR supports research that inspires hope among those impacted by the disease and advances opportunities for real results. For more information, contact us.